|Systematic (IUPAC) name|
|Bioavailability||Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours|
|Half life||19-24 hours|
Phendimetrazine (Bontril®) is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.
Phendimetrazine is used clinically in the form of phendimetrazine tartrate.
Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction.
According to the "List of psychotropic substances under international control," phendimetrazine is a Schedule IV controlled substance.
Phendimetrazine is listed as a Schedule III substance under the U.S. Controlled Substance Act in the 2007 Drug Identification Bible, pg 615 and under Section 11056(b)(6) California Health & Safety Code.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies